(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2013 (10.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/006834 A1

(51) International Patent Classification:
A61K 9/127 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2012/045840

(22) International Filing Date:
6 July 2012 (06.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/505,091 6 July 2011 (06.07.2011) US
61/585,639 11 January 2012 (11.01.2012) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRITO, Luis** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **CHAN, Michelle** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **GEALL, Andrew** [GB/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **O'HAGAN, Derek** [GB/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **SINGH, Manmohan** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(74) Agents: **LEE, Helen** et al.; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/006834 A1

(54) Title: OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS

(57) Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.